170 related articles for article (PubMed ID: 32649295)
1. Efficacy and safety of denosumab treatment in a prepubertal patient with cherubism.
Kawamura H; Watanabe S; I T; Asahina I; Moriuchi H; Dateki S
J Pediatr Endocrinol Metab; 2020 Jul; 33(7):963-966. PubMed ID: 32649295
[TBL] [Abstract][Full Text] [Related]
2. Positive Outcomes of Denosumab Treatment in 2 Patients With Cherubism.
Bar Droma E; Beck-Rosen G; Ilgiyaev A; Fruchtman Y; Abramovitch-Dahan C; Levaot N; Givol N
J Oral Maxillofac Surg; 2020 Dec; 78(12):2226-2234. PubMed ID: 32649899
[TBL] [Abstract][Full Text] [Related]
3. Denosumab Therapy in Cherubism.
Liles SI; C Hoppe I; Arnold L
Cleft Palate Craniofac J; 2023 Dec; 60(12):1665-1673. PubMed ID: 35821585
[TBL] [Abstract][Full Text] [Related]
4. Molecular and cellular characterizations of human cherubism: disease aggressiveness depends on osteoclast differentiation.
Kadlub N; Sessiecq Q; Mandavit M; L'Hermine AC; Badoual C; Galmiche L; Berdal A; Descroix V; Picard A; Coudert AE
Orphanet J Rare Dis; 2018 Sep; 13(1):166. PubMed ID: 30236129
[TBL] [Abstract][Full Text] [Related]
5. Rescue of a cherubism bone marrow stromal culture phenotype by reducing TGFβ signaling.
Liu Y; Sharma T; Chen IP; Reichenberger E; Ueki Y; Arif Y; Parisi D; Maye P
Bone; 2018 Jun; 111():28-35. PubMed ID: 29530719
[TBL] [Abstract][Full Text] [Related]
6. The calcineurin inhibitor tacrolimus as a new therapy in severe cherubism.
Kadlub N; Vazquez MP; Galmiche L; L'Herminé AC; Dainese L; Ulinski T; Fauroux B; Pavlov I; Badoual C; Marlin S; Deckert M; Leboulanger N; Berdal A; Descroix V; Picard A; Coudert AE
J Bone Miner Res; 2015 May; 30(5):878-85. PubMed ID: 25491283
[TBL] [Abstract][Full Text] [Related]
7. Cherubism Mice Also Deficient in c-Fos Exhibit Inflammatory Bone Destruction Executed by Macrophages That Express MMP14 Despite the Absence of TRAP+ Osteoclasts.
Kittaka M; Mayahara K; Mukai T; Yoshimoto T; Yoshitaka T; Gorski JP; Ueki Y
J Bone Miner Res; 2018 Jan; 33(1):167-181. PubMed ID: 28914985
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumor necrosis factor treatment in cherubism--clinical, radiological and histological findings in two children.
Hero M; Suomalainen A; Hagström J; Stoor P; Kontio R; Alapulli H; Arte S; Toiviainen-Salo S; Lahdenne P; Mäkitie O
Bone; 2013 Jan; 52(1):347-53. PubMed ID: 23069372
[TBL] [Abstract][Full Text] [Related]
9. Clinicoradiologic features of cherubism: a case report and literature review.
Dyasanoor S; Naik S
Gen Dent; 2014; 62(5):e12-5. PubMed ID: 25184726
[TBL] [Abstract][Full Text] [Related]
10. Cherubism: A Case Report with Surgical Intervention.
Friedrich RE; Scheuer HA; Zustin J; Grob T
Anticancer Res; 2016 Jun; 36(6):3109-15. PubMed ID: 27272835
[TBL] [Abstract][Full Text] [Related]
11. Use of Denosumab in Children With Osteoclast Bone Dysplasias: Report of Three Cases.
Upfill-Brown A; Bukata S; Bernthal NM; Felsenfeld AL; Nelson SD; Singh A; Wesseling-Perry K; Eilber FC; Federman NC
JBMR Plus; 2019 Oct; 3(10):e10210. PubMed ID: 31687646
[TBL] [Abstract][Full Text] [Related]
12. The role of SH3BP2 in the pathophysiology of cherubism.
Reichenberger EJ; Levine MA; Olsen BR; Papadaki ME; Lietman SA
Orphanet J Rare Dis; 2012 May; 7 Suppl 1(Suppl 1):S5. PubMed ID: 22640988
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Toxicity of Calcitonin Treatment in Children with Cherubism: A Single-Center Cohort Study.
Schreuder WH; Meijer EB; Cleven AHG; Edelenbos E; Klop C; Schreurs R; de Jong RT; van Maarle MC; Horsthuis RBG; de Lange J; van den Berg H
J Bone Miner Res; 2023 Dec; 38(12):1822-1833. PubMed ID: 37823782
[TBL] [Abstract][Full Text] [Related]
14. Fine needle aspiration cytologic features of Cherubism: a case report.
Gupta N; Duggal R; Rajwanshi A; Rattan V
Acta Cytol; 2010; 54(4):595-7. PubMed ID: 20715662
[TBL] [Abstract][Full Text] [Related]
15. Aggressive case of cherubism: 17-year follow-up.
Pontes FS; Ferreira AC; Kato AM; Pontes HA; Almeida DS; Rodini CO; Pinto DS
Int J Pediatr Otorhinolaryngol; 2007 May; 71(5):831-5. PubMed ID: 17360048
[TBL] [Abstract][Full Text] [Related]
16. Defining a new aggressiveness classification and using NFATc1 localization as a prognostic factor in cherubism.
Kadlub N; Sessiecq Q; Dainese L; Joly A; Lehalle D; Marlin S; Badoual C; Galmiche L; Majoufre-Lefebvre C; Berdal A; Deckert M; Vazquez MP; Descroix V; Coudert AE; Picard A
Hum Pathol; 2016 Dec; 58():62-71. PubMed ID: 27498064
[TBL] [Abstract][Full Text] [Related]
17. Second-Generation SYK Inhibitor Entospletinib Ameliorates Fully Established Inflammation and Bone Destruction in the Cherubism Mouse Model.
Yoshimoto T; Hayashi T; Kondo T; Kittaka M; Reichenberger EJ; Ueki Y
J Bone Miner Res; 2018 Aug; 33(8):1513-1519. PubMed ID: 29669173
[TBL] [Abstract][Full Text] [Related]
18. Treatment of central giant cell granuloma in children with denosumab.
Choe M; Smith V; Okcu MF; Wulff J; Gruner S; Huisman TAGM; Venkatramani R
Pediatr Blood Cancer; 2021 Mar; 68(3):e28778. PubMed ID: 33089644
[TBL] [Abstract][Full Text] [Related]
19. Multinucleated giant cells in various forms of giant cell containing lesions of the jaws express features of osteoclasts.
Liu B; Yu SF; Li TJ
J Oral Pathol Med; 2003 Jul; 32(6):367-75. PubMed ID: 12787044
[TBL] [Abstract][Full Text] [Related]
20. SH3BP2 is rarely mutated in exon 9 in giant cell lesions outside cherubism.
Lietman SA; Prescott NL; Hicks DG; Westra WH; Levine MA
Clin Orthop Relat Res; 2007 Jun; 459():22-7. PubMed ID: 17545756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
